Federal Register, Volume 86 Issue 16 (Wednesday, January 27, 2021)

[Federal Register Volume 86, Number 16 (Wednesday, January 27, 2021)]
[Notices]
[Pages 7294-7296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01740]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


National Center for Health Statistics (NCHS), ICD-10 Coordination 
and Maintenance (C&M) Committee Meeting

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The CDC, National Center for Health Statistics (NCHS), 
Classifications and Public Health Data Standards Staff, announces the 
following meeting of the ICD-10 Coordination and Maintenance (C&M) 
Committee meeting. This meeting is open to the public, limited only by 
audio lines available. Online Registration is not required.

DATES: The meeting will be held on March 9, 2021, from 9:00 a.m. to 
5:00 p.m., EDT, and March 10, 2021, from 9:00 a.m. to 5:00 p.m., EDT.

ADDRESSES: This is a virtual meeting. Information will be provided on 
each of our respective web pages when it becomes available. For CDC/
NCHS https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For CMS 
https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.

FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Program Specialist, 
CDC, 3311 Toledo Road, Hyattsville, Maryland 20782, Telephone (301) 
458-4454; [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is 
a public forum for the presentation of proposed modifications to the 
International Classification of Diseases, Tenth Revision, Clinical 
Modification and ICD-10 Procedure Coding System.

[[Page 7295]]

    Matters To Be Considered: The tentative agenda will include 
discussions on ICD-10-CM and ICD-10-PCS topics listed below. Agenda 
items are subject to change as priorities dictate. Please refer to the 
posted agenda for updates one month prior to the meeting.

ICD-10-PCS Topics

1. Administration of Trilaciclib *
2. Administration of ZEPZELCA^TM (lurbinectedin) *
3. Administration of ENSPRYNG^TM (satralizumab-mwge) *
4. Administration of ciltacabtagene autoleucel (cilta-cel) *
5. Administration of Amivantamab *
6. Administration of Molnupiravir *
7. Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen 
Complex (PRCFC) *
8. Administration of OTL-103
9. Administration of OTL-200
10. Application of Topical Agent for Non-Excisional Eschar Removal *
11. Application of Bioengineered Skin Construct *
12. Computer-Aided Assessment, Characterization and Notification 
Software for Head CT Scan *
13. Computer-Aided Detection, Triage and Notification Software for 
Acute Subdural Hemorrhage with Non-Contrast CT of the Head *
14. Computer-Aided Detection, Triage and Notification Software for 
Computed Tomography Pulmonary Angiography (CTPA) *
15. Computer-Aided Detection, Triage and Notification Software for 
Stroke with Non-Contrast CT of the Head *
16. Transthoracic Echocardiography with AI-Guide Image Acquisition *
17. Tissue Oxygen Saturation Imaging of GI Tract *
18. Mechanical Thrombectomy using AI Assistance *
19. Transcatheter Replacement of Pulmonary Valve *
20. Combined Thoracic Aortic Arch Replacement and Descending 
Thoracic Aorta Restriction *
21. Extraluminal Autologous Saphenous Vein Graft Support *
22. Coronary Intravascular Lithotripsy (IVL) *
23. Percutaneous Creation of an Arterio-Venous Fistula (AVF) *
24. Pharyngeal Electrical Stimulation *
25. Patient Specific Intervertebral Body Fusion *
26. Colonic Irrigation for Colonoscopy *
27. Blood Collection Utilizing Specimen Diversion *
28. Concurrent Measurement of mRNA, PCR test and Detection of 
Antibodies *
29. Metal Ureteral Stents
30. Regional Anticoagulation for Renal Replacement Therapy
31. Gene Expression Assay
32. Total Artificial Heart Systems
33. Tourniquets Used for Acute Hemorrhage Control
34. Measurement of Flow in a Cerebral Fluid Shunt
35. Endoscopic Suturing Device for Upper and Lower GI Procedures
36. Section X Updates
37. Addenda and Key Updates
    * Applicant has submitted a New Technology Add-on Payment (NTAP) 
application for FY 2022.

    Presentations for procedure code requests are conducted by both the 
requestor and CMS during the Coordination & Maintenance Committee 
meeting. Discussion from the requestor generally focuses on the 
clinical issues for the procedure or technology, followed by the 
proposed coding options from a CMS analyst. Topics presented may also 
include requests for new procedure codes that relate to a new 
technology add-on payment (NTAP) policy request.
    CMS is modifying the approach for presenting the new technology 
add-on payment (NTAP) related ICD-10-PCS procedure code requests that 
involve the administration of a therapeutic agent for the March 9-10, 
2021 ICD-10 Coordination and Maintenance Committee meeting due to the 
volume of NTAP applications and corresponding procedure code requests 
being considered for FY 2022. Consistent with the requirements of 
section 1886(d)(5)(K)(iii) of the Social Security Act, applicants 
submitted requests to create a unique procedure code to describe the 
administration of a therapeutic agent, such as the option to create a 
new code in Section X within the ICD-10-PCS procedure code 
classification. In order to accommodate the number of requests received 
for the March 9-10, 2021 ICD-10 Coordination and Maintenance Committee 
meeting, CMS will initially only display those meeting materials 
associated with the NTAP related ICD-10-PCS procedure code requests 
that involve the administration of a therapeutic agent on the CMS 
website in early February 2021 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials.
    The six NTAP related ICD-10-PCS procedure code requests that 
involve the administration of a therapeutic agent are:

1. Administration of Trilaciclib
2. Administration of ZEPZELCA^TM (lurbinectedin)
3. Administration of ENSPRYNG^TM (satralizumab-mwge)
4. Administration of Ciltacabtagene Autoleucel (cilta-cel)
5. Administration of Amivantamab
6. Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen 
Complex (PRCFC)

    These topics will not be presented during the March 9-10, 2021 
meeting. CMS will solicit public comments regarding any clinical 
questions or coding options included for these six procedure code 
topics in advance of the meeting continuing through the end of the 
public comment period, April 9, 2021. Members of the public should send 
any questions or comments to the CMS mailbox at: 
[email protected] by the April 9, 2021 deadline.
    CMS intends to post a question and answer document in advance of 
the meeting to address any clinical or coding questions that members of 
the public may have submitted. Following the conclusion of the meeting, 
CMS will post an updated question and answer document to address any 
additional clinical or coding questions that members of the public may 
have submitted during the meeting that CMS was not able to address or 
that were submitted after the meeting.
    The NTAP related ICD-10-PCS procedure code requests that do not 
involve the administration of a therapeutic agent and all non-NTAP 
related procedure code requests will continue to be presented during 
the virtual meeting on March 9, 2021 consistent with the standard 
meeting process.
    CMS will make all meeting materials and related documents available 
at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled 
for the March 9-10, 2021 ICD-10 Coordination and Maintenance Committee 
meeting that are under consideration for October 1, 2021 implementation 
should be sent to the CMS mailbox at: 
[email protected].

ICD-10-CM Topics

1. Anatomical Flank Specificity
2. ANCA vasculitis
3. Apnea related conditions of Newborn
4. Atrial and Atrioventricular Septal Defect
5. Alzheimer's/Vascular Dementia
6. Endometriosis
7. Limb girdle muscular dystrophies expansion
8. Lumbar disc degeneration, with pain
9. Mild Cognitive Disorder due to Physiological Conditions 
(representation)
10. Prolonged Grief Disorder
11. Refractory Angina Pectoris
12. Rheumatic mitral valve leaflet calcification
13. Slipped Upper Femoral Epiphysis
14. Short Stature due to Endocrine Disorder
15. Substance Use Disorder, unspecified, in remission
16. Torsade de pointes expansion
17. Von Willebrand Disease

[[Page 7296]]

18. Addenda

    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-01740 Filed 1-26-21; 8:45 am]
BILLING CODE 4163-18-P